Ever wondered if ResMed stock is actually a steal or quietly overhyped? You're not alone. This article will dig beneath the surface to find out. Shares have seen modest gains recently, with the price ...

ResMed posted a 9% revenue increase and an 11% rise in net income for the September quarter, driven by increased demand for sleep treatment products. The company demonstrated strong growth in various ...

ResMed (NASDAQ:RMD) Chief Executive Officer Michael J. Farrell sold 8,009 shares of company stock on October 7, 2025, for approximately $2.26 million. The sales were executed in multiple trades at ...

Milestones underscore Resmed's leadership and commitment to delivering life-changing health technology that people love SAN DIEGO, Aug. 21, 2025nasal cradle mask won two prestigious Red Dot Awards: ...

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its ...

Resmed Inc (NYSE:RMD) reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of ...

July 31 (Reuters) - Resmed (RMD.N), opens new tab beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea. The company ...

Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above ...

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) — Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has ...

Sleep device maker ResMed says it has received an exemption from Donald Trump’s trade tariffs, meaning exports from its manufacturing hubs in Australia and Singapore can dodge the US president’s ...

ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, ...